← Back to dashboard
Stryker
Stryker's Mako franchise makes it one of the clearest scaled robotics names in orthopedics.
Metric timing
This page mixes live market data, trailing fundamentals, and latest reported statement data.
Live / market snapshot
Price, 1D change, market cap, and enterprise value are current market-based figures.
TTM / forward
Most valuation and margin cards are trailing twelve months, while forward P/E uses forward consensus.
Latest quarter / dividend cadence
Balance-sheet ratios use the latest reported quarter. Dividend cadence is inferred from recent payout history.
latest annual revenue
latest quarterly revenue
latest annual profit
latest quarterly profit
annualized per share
latest ex-dividend cash amount
Latest headlines
Recent company headlines. Each link opens the original article in a new tab.
The Robotic Surgery Leader: Intuitive Surgical Slides Further But One Wall Street Bull Pegs Returns at 85%
Intuitive Surgical has shed a third of its value while its robotic surgery peers barely flinched, and Wall Street's most bullish analyst sees an outcome that would leave anyone who sold near the bottom regretting it.
Stryker (SYK) Q2 2026 Earnings Call TranscriptCEO Lobo discusses 9% organic sales growth and margin expansion amid cybersecurity recovery.
Solventum (SOLV) Appoints Neil Zieselman As New Chief Accounting OfficerSolventum (NYSE:SOLV) has appointed Neil Zieselman as Senior Vice President, Controller, and Chief Accounting Officer. He will succeed current Controller and Chief Accounting Officer Mary Wilcox following her retirement. Zieselman brings experience from Surgery Partners Inc., Stryker Corporation, Covanta Holding Corporation, Cendant Corporation, and Avaya Inc., and is a licensed CPA. Solventum enters this leadership change with its stock at $85.44 and a value score of 5, which can help...
Is Stryker (SYK) Undervalued As Earnings Trigger A Fresh Valuation Question?Stryker (SYK) is back in focus after its second quarter 2026 earnings, reporting sales of US$6.59b and net income of US$1.28b, alongside a sharp market reaction to the release. See our latest analysis for Stryker. The 1 day share price return of Stryker fell 6.42% on the earnings release, which pulled the year to date share price return down 6.46%, while the 5 year total shareholder return of 30.66% still reflects longer term gains. If Stryker’s move has you reassessing healthcare exposure,...
How Strong Q2 Earnings, Raised Guidance and Cyber Recovery Will Impact Stryker (SYK) InvestorsStryker Corporation’s recently reported Q2 2026 results showed sales rising to US$6,589 million and net income to US$1,276 million, with both basic and diluted EPS from continuing operations increasing compared with the prior year period. Management also highlighted 9% organic sales growth, recovery progress after a March cyberattack that disrupted operations, and a slight increase to full-year adjusted EPS guidance while planning to resume share repurchases. We will now examine how this...
SYK Q2 Deep Dive: Supply Chain Disruptions Weigh on Growth Outlook Despite Margin ExpansionMedical technology company Stryker (NYSE:SYK) met Wall Street’s revenue expectations in Q2 CY2026, with sales up 9.4% year on year to $6.59 billion. Its non-GAAP profit of $3.69 per share was 5.8% above analysts’ consensus estimates.
Why it could benefit going forward
- Stryker's Mako franchise makes it one of the clearest scaled robotics names in orthopedics.
- Recent expansion into handheld robotics broadens the Mako platform and gives the sleeve another real medical-robotics leader.
- It adds exposure to hospital robotics without relying on the exact same thesis as Intuitive.
Moat / edge
- Established Mako installed base and surgeon workflow integration.
- Strong orthopedic distribution and clinical relationships.
- A robotics platform that can expand across procedures over time.
What to watch
- Mako placements and utilization.
- Adoption of new handheld robotics offerings.
- How much robotics continues to differentiate Stryker in orthopedics.
Key risks
- Hospital budgets and elective procedure trends can affect demand.
- The robotics narrative is important, but it still sits inside a broader medtech company.
Business snapshot
Stryker Corporation operates as a medical technology company in the United States and internationally. It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics. The MedSurg and Neurotechnology segment offers surgical equipment, patient and caregiver safety technologies, navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, clinical communication and artificial intelligence-assisted virtual care platform technology, and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke and venous thromboembolism; traditional brain and open skull based surgical procedures products; and orthobiologic and biosurgery products, including synthetic bone grafts and vertebral augmentation products. The Orthopaedics segment provides implants for use in total joint replacements, such as hip, knee and shoulder, ankle, and trauma and extremities surgeries; and Mako Shoulder, which expands the smart robotics suite of applications. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 61 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.